Objective: Based on the network pharmacology method, the active ingredient gene target network and protein interaction network of Acorus tatarinowii were constructed, and the functions and signaling pathways involved in the obtained gene targets were analyzed, so as to explore the possible mechanism of action of Acorus tatarinowii in the treatment of ischemic stroke. Methods: TCMSP, UniprotKB, Genecards, TTD, OMIM and Drugbank were used to search the main active components of Acorus tatarinowii and the target of Acorus tatarinowii in the treatment of ischemic stroke. The STRING database and Cytoscape3.8.2 software were used to construct the protein-protein interaction network and analyze it to predict the core protein targets of Acorus tatarinowii in the treatment of ischemic stroke. KEGG and GO analysis of key genes were performed using Metascape database to predict possible signaling pathways and biological processes. Results: Four active compounds and 76 corresponding action targets of Acorus tatarinowii was retrieved from TCMSP database. PPI network has 45 core target proteins. KEGG enrichment analysis predicted possible pathways including fluid shear stress, cGMP-PKG signaling pathway, NF-Kappa B signaling pathway, HIF-1 signaling pathway, VEGF signaling pathway, AMPK signaling pathway, etc. GO enrichment analysis of possible biological processes included circulatory system processes, reactive oxygen metabolism, responses to oxygen levels, endothelial cell migration, and exogenous apoptotic signaling pathways. Molecular docking results showed that kaempferol could stably bind to MAPK8, VCAM1, ICAM1, HMOX1 and PPARG, and 8-isopentenylkaempferol could stably bind to PPARG, MAPK14 and ESR1.Conclusions: This study found that Acorus tatarinowii may play a therapeutic role in the treatment of ischemic stroke from anti-inflammatory, anti-oxidation, promoting new angiogenesis and other aspects, providing a new idea and theoretical basis for the clinical application and clinical drug research and development of Acorus tatarinowii
Objective: To systematically evaluate the efficacy of staging-acupuncture therapy on peripheral facial paralysis. Methods: The clinical trials regarding acupuncture therapy for peripheral facial paralysis published before December 31st 2021 were searched in databases of PubMed, The Cochrane Library, Web of Science, CNKI, WanFang, VIP and CBM. The information of included studies was extracted and the quality was assessed by two independent researchers. The Metaanalysis was performed by using RevMan 5.4 software. Results: A total of 8 trials were included, involving 1224 cases. The results of Meta-analysis showed that: The markedly effective rate of staging-acupuncture group was higher than of the non-staging group [RR=1.23, 95%CI(1.15,1.32), Z=6.02, P<0.01]. Conclusion: Based on the current evidence, the efficacy of staging-acupuncture therapy on facial paralysis is superior to non-staging acupuncture therapy. But for the quantity and quality of the included trials are not satisfactory, the conclusion still needs more high-quality, large-size and randomized controlled trials.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.